AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
02 Apr 2013 07:00 AM
RNS
US court says one PULMICORT patent invalid
27 Mar 2013 02:30 PM
RNS
Director/PDMR Shareholding
27 Mar 2013 02:30 PM
RNS
Director/PDMR Shareholding
26 Mar 2013 03:13 PM
RNS
Director/PDMR Shareholding
26 Mar 2013 07:00 AM
RNS
Filing of Annual Report on Form 20-F with SEC
25 Mar 2013 11:38 AM
RNS
Annual Financial Report
25 Mar 2013 07:00 AM
RNS
AstraZeneca settles over Crestor patent
21 Mar 2013 07:00 AM
RNS
AstraZeneca announces agreement with Moderna
21 Mar 2013 07:00 AM
RNS
AstraZeneca partners Karolinska Institute
21 Mar 2013 07:00 AM
RNS
AstraZeneca outlines growth strategy
18 Mar 2013 01:00 PM
RNS
AstraZeneca to establish strategic R&D centres
14 Mar 2013 10:00 AM
RNS
Block Listing Application
05 Mar 2013 07:00 AM
RNS
Australian court holds crestor patents invalid
01 Mar 2013 04:00 PM
RNS
Total Voting Rights
27 Feb 2013 10:00 AM
RNS
Director/PDMR Shareholding
27 Feb 2013 10:00 AM
RNS
Director/PDMR Shareholding
27 Feb 2013 10:00 AM
RNS
Director/PDMR Shareholding
27 Feb 2013 10:00 AM
RNS
Director/PDMR Shareholding
01 Feb 2013 04:00 PM
RNS
Total Voting Rights
31 Jan 2013 07:00 AM
RNS
Final Results
31 Jan 2013 07:00 AM
RNS
Final Results
30 Jan 2013 09:00 AM
RNS
Notice of Results
15 Jan 2013 01:00 PM
RNS
Announces changes to Senior Executive Team
02 Jan 2013 04:00 PM
RNS
Total Voting Rights
28 Dec 2012 03:58 PM
RNS
Director/PDMR Shareholding
14 Dec 2012 05:56 PM
RNS
CRESTOR US Patent Upheld
13 Dec 2012 02:59 PM
RNS
Top-line results of OSKIRA-4
07 Dec 2012 02:30 PM
RNS
Director/PDMR Shareholding
06 Dec 2012 02:30 PM
RNS
Director/PDMR Shareholding
03 Dec 2012 03:00 PM
RNS
Total Voting Rights
03 Dec 2012 03:00 PM
RNS
Blocklisting Interim Review
22 Nov 2012 02:30 PM
RNS
Director/PDMR Shareholding
21 Nov 2012 02:30 PM
RNS
Director/PDMR Shareholding
15 Nov 2012 04:30 PM
RNS
Director/PDMR Shareholding
14 Nov 2012 04:49 PM
RNS
FORXIGA first in class SGLT2 gets EU approval
12 Nov 2012 04:30 PM
RNS
Definition of Core Financial Measures
12 Nov 2012 07:00 AM
RNS
Top-line phase III results for Naloxegol
01 Nov 2012 03:00 PM
RNS
Total Voting Rights
29 Oct 2012 01:10 PM
RNS
Director/PDMR Shareholding
29 Oct 2012 01:10 PM
RNS
Director/PDMR Shareholding
25 Oct 2012 07:00 AM
RNS
3rd Quarter Results
24 Oct 2012 09:00 AM
RNS
Notice of Results
01 Oct 2012 04:30 PM
RNS
Total Voting Rights
01 Oct 2012 02:00 PM
RNS
AstraZeneca suspends share repurchase programme
26 Sep 2012 07:00 AM
RNS
Transaction in Own Shares
25 Sep 2012 07:00 AM
RNS
Transaction in Own Shares
19 Sep 2012 08:48 AM
RNS
Transaction in Own Shares
18 Sep 2012 07:00 AM
RNS
Transaction in Own Shares
17 Sep 2012 07:00 AM
RNS
Transaction in Own Shares
14 Sep 2012 07:00 AM
RNS
Transaction in Own Shares

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings